Statera BioPharma Inc (STAB)

[mick]

History

2014
December – Dosed first cancer patient with entolimod in Russian Federation
October – Opened IND for entolimod in the Russian Federation
October – Dosed first healthy subject with CBLB612 in Russian Federation
September – Achieved agreement with FDA that existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod’s biodefense indication
September – Completed enrollment of Phase 1 advanced cancer trial with entolimod at Roswell Park Cancer Institute
August – Opened IND for CBLB612 in the Russian Federation
April – Reported Phase 1 trial for CBL0102 (predecessor to CBL0137)

http://www.cbiolabs.com/history